BEDFORD, Mass.–(BUSINESS WIRE)– Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced the executive appointments of Stephen R. Mascioli, M.D., MPH, to the role of Chief Medical Officer (CMO) and Dana M. Alexander to the role of Chief Operations Officer (COO). Dr. Mascioli and Mr. Alexanderwill report to Anika’s President and Chief Executive Officer, Charles H. Sherwood, Ph.D.
“We’re pleased to add Dr. Mascioli and Mr. Alexander to our executive leadership team as we enter a pivotal phase in Anika’s growth, which is driven by pipeline advancement and global commercial expansion,” said Dr. Sherwood. “With Dr. Mascioli spearheading the preclinical and clinical development of our robust pipeline and Mr. Alexander overseeing and building our manufacturing and operations capabilities, we anticipate tremendous progress in executing our long-term growth strategy.”
Dr. Mascioli, a medical executive with 25 years of leadership experience, previously held the inaugural CMO position at Terumo Americas Holdings, where his primary responsibilities included establishing the build-out of the company’s medical department, providing strategic leadership for regulatory and clinical programs, and managing risk assessment and mitigation analysis on patient safety issues. Prior to joining Terumo, Dr. Mascioliserved as CMO of the Vascular Therapies division of Covidien, a global medical device company, and he also held senior medical leadership positions at Boston Scientific and American Medical Systems. Dr. Mascioli holds a M.D. from Boston University School of Medicine, a Master’s Degree in Public Health from the University of Minnesota School of Public Health, and a Bachelor of Arts Degree in Biology from Brandeis University. Click here to view Dr. Mascioli’s full bio.
“Anika has an impressive track record in research and development, which has led to a solid and diversified pipeline that spans the continuum from pain management to healing, repair, and regeneration,” said Dr. Mascioli. “I’m excited to drive the clinical development strategy, rally the support of key physician thought leaders, and work with our regulatory team to bring Anika’s important therapeutic advances to patients.”
Mr. Alexander brings nearly two decades of operational expertise in manufacturing and supply chain management, and he spent the last 14 years in various leadership roles at Genzyme Corporation. Prior to assuming his position as Chief Operations Officer at Anika, Mr. Alexander served as Senior Director of Biologics Manufacturing Operations, where he led manufacturing at Genzyme’s flagship biologics plant including overseeing production planning and execution, bringing new manufacturing capacity on-line, and implementing new production and quality systems. During his tenure at Genzyme, Mr. Alexander provided operational oversight for the construction, start-up, and approval of a new cGMP cell culture facility, managed Chemistry, Manufacturing, and Control (CMC) activities for a variety of late stage and commercial products, and led operation product teams across complex supply chains to deliver global clinical and commercial supply requirements. Mr. Alexander holds a Master’s Degree in Business Administration from Boston University, and a Bachelor of Science Degree in Chemical Engineering from Northeastern University. Click here to view Mr. Alexander’s full bio.
“I look forward to building upon Anika’s strong operational framework and processes to establish a manufacturing and production powerhouse that will function as the cornerstone of Anika’s global commercial expansion effort,” said Mr. Alexander.
As part of its direct commercialization buildout, Anika also expanded its commercial team with the hire of Ms. Jean A. Bjerke as Vice President of Marketing. Ms. Bjerke will report to Richard Hague, Anika’s Chief Commercial Officer, and her primary focus areas will be global and domestic market development and commercial launch planning and execution. Prior to joining Anika, Ms. Bjerke spent 15 years specializing in marketing with the orthopedic device segments for Smith & Nephew and Depuy Orthopedics.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedics medicines company based in Bedford, Mass. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions by providing clinically meaningful therapeutic pain management solutions along the continuum of care, from palliative care to regenerative medicine. The Company has over two decades of expertise developing, manufacturing and commercializing more than 20 products, in markets across the globe, based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio is comprised of marketed (ORTHOVISC® and MONOVISC®) and pipeline (CINGAL® and HYALOFAST® in the U.S.) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration. For more information about Anika, please visit http://www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the second, fourth, and sixth paragraphs of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s progress on its growth strategy, delivery of its products to the market, and manufacturing and production capabilities. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (x) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website atwww.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160404005126/en/
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
or
For Media Inquiries:
Pure Communications
Susan Heins, 864-286-9597
Source: Anika Therapeutics, Inc.
News Provided by Acquire Media
